Merck/Pfizer up the pressure on BMS in first-line kidney cancerThe FDA has started a speedy review of Merck KGaA and Pfizer’s new combination regimen for advanced kidney Share XMerck/Pfizer up the pressure on BMS in first-line kidney cancerhttps://pharmaphorum.com/news/merck-pfizer-up-the-pressure-on-bms-in-first-line-kidney-cancer/
Inspiring a new generation of women in pharmaAs part of a series of articles highlighting the role of women in the pharma industry, Richard Staines Share XInspiring a new generation of women in pharmahttps://pharmaphorum.com/views-and-analysis/inspiring-a-new-generation-of-women-in-pharma/
MSD and Pfizer top Dow for 2018MSD and Pfizer were 2018’s top gainers on the Dow Jones Industrial Average for the calendar year, with Share XMSD and Pfizer top Dow for 2018https://pharmaphorum.com/news/msd-and-pfizer-top-dow-for-2018/
Sanofi, Merck’s Vaxelis is first six-in-one vaccine in USSanofi and Merck & Co picked up late 2018 approval from the FDA during the holiday period, getting Share XSanofi, Merck’s Vaxelis is first six-in-one vaccine in UShttps://pharmaphorum.com/news/sanofi-mercks-vaxelis-is-first-six-in-one-vaccine-in-us/
Merck takes a back seat on CAR-T, handing assets to IntrexonMerck KGaA wants to get bigger in immuno-oncology, but from now on it won’t be taking a direct Share XMerck takes a back seat on CAR-T, handing assets to Intrexonhttps://pharmaphorum.com/news/merck-takes-a-back-seat-on-car-t-handing-assets-to-intrexon/
Merck bags adjuvant okay for Keytruda in melanomaCheckpoint inhibitors have already revolutionised the treatment of advanced melanoma, and Merck & Co has just claimed approval Share XMerck bags adjuvant okay for Keytruda in melanomahttps://pharmaphorum.com/news/merck-bags-adjuvant-okay-for-keytruda-in-melanoma/
Merck and Pfizer chalk up another fail for BavencioMerck KGaA and Pfizer’s late entrant to the checkpoint inhibitor category has failed a phase III trial in Share XMerck and Pfizer chalk up another fail for Bavenciohttps://pharmaphorum.com/news/merck-and-pfizer-chalk-up-another-fail-for-bavencio/
Merck gets FDA okay for Keytruda as liver cancer therapyMerck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular Share XMerck gets FDA okay for Keytruda as liver cancer therapyhttps://pharmaphorum.com/news/merck-gets-fda-okay-for-keytruda-as-liver-cancer-therapy/
Exclusive Live coverage: Curious2018 Future Insight: Day 3Curious2018 – Future Insight is a new flagship healthcare conference launched this year by Merck to bring some Share XExclusive Live coverage: Curious2018 Future Insight: Day 3https://pharmaphorum.com/views-and-analysis/exclusive-live-coverage-curious2018-future-insight-day-3/
